Marshall Wace, LLP Krystal Biotech, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $7.05 Million - $11.7 Million	-65,301 Reduced 92.1%	5,600 $996,000
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $5.89 Million - $7.87 Million	61,373 Added 644.13%	70,901 $8.8 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $1.03 Million - $1.24 Million	9,528 New	9,528 $1.11 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $262,703 - $305,815	-3,629 Reduced 29.75%	8,571 $686,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $770,308 - $974,780	12,200 New	12,200 $966,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $5.64 Million - $7.82 Million	-108,511 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $3.3 Million - $7.31 Million	82,856 Added 322.96%	108,511 $7.59 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.33 Million - $1.84 Million	25,655 New	25,655 $1.34 Million
Q2 2021 Aug 13, 2021	SELL	$62.14 - $81.82 $1.85 Million - $2.44 Million	-29,836 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $1.33 Million - $1.92 Million	22,409 Added 301.72%	29,836 $2.3 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $301,833 - $455,869	7,427 New	7,427 $446,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.